Trevi Therapeutics Inc Sustainability Reports
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing its investigational therapy, Haduvio (oral nalbuphine extended-release), for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG003QGQRC8
4 reports from 2019 to 2024